Thibaud Prawitz
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective.
Journal: Antimicrobial agents and chemotherapy
Published: August 27, 2025
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Journal: Clinical lung cancer
Published: July 21, 2023
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
Journal: Advances in therapy
Published: January 25, 2023
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 20, 2023
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Journal: Advances in therapy
Published: January 03, 2022
Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment.
Journal: Journal of clinical epidemiology
Published: September 13, 2021
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Journal: Advances in therapy
Published: April 20, 2021
How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: May 13, 2020
Personalized benefit-risk assessments combining clinical trial and real-world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy.
Journal: Pharmacoepidemiology and drug safety
Published: October 29, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026